REDWOOD CITY, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), a commercial-stage biopharmaceutical company focused on the research, development, and commercialization of innovative immunotherapies to treat cancer, announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the…Read More
FDA Issues Complete Response Letter CRL for UDENYCA ONBODY Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a ThirdParty Filler Coherus Also Announces Completion of Toripalimab FDA Inspections
